Degradable Endometrial Repair Membrane Multicenter Clinical Trial Completes Nationwide Enrollment, Marking a Milestone for NuoYiMaiER in Women's Health Innovation

Recently, the multi-center clinical trial of Neo Modulus' biodegradable endometrial repair membrane has successfully completed enrollment across China. This clinical trial was led by Professor Lei Yan from the Reproductive Hospital Affiliated with Shandong University, bringing together top clinical experts from several well-known medical institutions across China. Neo Modulus sincerely thanks the participants, scholars, and all clinical staff who took part in and supported this research.

As applied to moderate and severe intrauterine adhesion separation surgery,The First Product in ChinaAn innovative product focused on endometrial repair and auxiliary prevention of intrauterine adhesion recurrence has been successfully selected.National Key Research and Development ProgramAnd the Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project), Neo Modulus' scientific research and innovation capabilities have been highly recognized.

The successful completion of this nationwide enrollment marks a critical breakthrough in the clinical research of this product. Currently, Neo Modulus is efficiently advancing the subsequent evaluation and approval processes, making every effort to accelerate the commercialization of the product and provide a higher quality innovative solution for the field of endometrial repair treatment.

In the future, Neo Modulus will always adhere to its core mission of "deciphering the regeneration code and safeguarding human health," deepen industry-university-research collaboration with scientific research institutions and clinical hospitals both in China and internationally, empower high-quality development in regenerative medicine through technological innovation, demonstrate the responsibility and commitment of a Chinese medical enterprise, and light up the hope of health for more patients.

Statement:

This article is for news purposes only, and its content is solely intended for information dissemination or industry exchange.Nothing herein shall be deemed as advertising or representing any express or implied advertisement, nor shall it be considered to contain any purpose of sale or promise of sale.For accurate information, please consult a professional medical institution and seek professional advice.

If any individual or media outlet, website wishes to reprint this article, please contact the official account for authorization and indicate the source of the reprint.

Copywriting: Jerry Typesetting: Jerry